Completed OBSERVATIONAL NCT01412398

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (FOSRENOL-CAPD)

Special Drug Use Investigation of Fosrenol (Investigation for Patients With Continuous Ambulatory Peritoneal Dialysis)

Sponsor: Bayer

Interventions Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Updated 7 times since 2017 Last updated: Jan 18, 2018 Started: Apr 7, 2009 Primary completion: Apr 8, 2014 Completion: Sep 1, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Hyperphosphatemia, this trial is completed. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Feb 2018 — Apr 2018 [monthly]

Completed NA

Phase: PHASE4 → NA
Jan 2017 — Feb 2018 [monthly]

Completed PHASE4

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Multiple Locations, Japan